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Abstract
Prostate biopsy is the current gold-standard procedure for prostate cancer diagnosis. Existing prostate biopsy
procedures have been mostly focusing on detecting cancer presence. However, they often ignore the potential
use of biopsy to estimate cancer volume (CV) and Gleason Score (GS, a cancer grade descriptor), the two
surrogate markers for cancer aggressiveness and the two crucial factors for treatment planning. To fill up this
vacancy, this paper assumes and demonstrates that, by optimally sampling the spatial patterns of cancer,
biopsy procedures can be specifically designed for estimating CV and GS. Our approach combines image
analysis and machine learning tools in an atlas-based population study that consists of three steps. First, the
spatial distributions of cancer in a patient population are learned, by constructing statistical atlases from
histological images of prostate specimens with known cancer ground truths. Then, the optimal biopsy
locations are determined in a feature selection formulation, so that biopsy outcomes (either cancer presence
or absence) at those locations could be used to differentiate, at the best rate, between the existing specimens
having different (high vs. low) CV/GS values. Finally, the optimized biopsy locations are utilized to estimate
whether a new-coming prostate cancer patient has high or low CV/GS values, based on a binary classification
formulation. The estimation accuracy and the generalization ability are evaluated by the classification rates
and the associated receiver-operating-characteristic (ROC) curves in cross validations. The optimized biopsy
procedures are also designed to be robust to the almost inevitable needle displacement errors in clinical
practice, and are found to be robust to variations in the optimization parameters as well as the training
populations.
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a b s t r a c t
Prostate biopsy is the current gold-standard procedure for prostate cancer diagnosis. Existing prostate
biopsy procedures have been mostly focusing on detecting cancer presence. However, they often ignore
the potential use of biopsy to estimate cancer volume (CV) and Gleason Score (GS, a cancer grade descrip-
tor), the two surrogate markers for cancer aggressiveness and the two crucial factors for treatment plan-
ning. To fill up this vacancy, this paper assumes and demonstrates that, by optimally sampling the spatial
patterns of cancer, biopsy procedures can be specifically designed for estimating CV and GS. Our approach
combines image analysis and machine learning tools in an atlas-based population study that consists of
three steps. First, the spatial distributions of cancer in a patient population are learned, by constructing
statistical atlases from histological images of prostate specimens with known cancer ground truths. Then,
the optimal biopsy locations are determined in a feature selection formulation, so that biopsy outcomes
(either cancer presence or absence) at those locations could be used to differentiate, at the best rate,
between the existing specimens having different (high vs. low) CV/GS values. Finally, the optimized
biopsy locations are utilized to estimate whether a new-coming prostate cancer patient has high or
low CV/GS values, based on a binary classification formulation. The estimation accuracy and the
generalization ability are evaluated by the classification rates and the associated receiver-operating-char-
acteristic (ROC) curves in cross validations. The optimized biopsy procedures are also designed to be
robust to the almost inevitable needle displacement errors in clinical practice, and are found to be robust
to variations in the optimization parameters as well as the training populations.
 2009 Elsevier B.V. All rights reserved.
1. Introduction
1.1. The need for estimating surrogate markers for cancer significance
In an aging population, prostate cancer continues to be the sec-
ond leading cause for cancer-related death in American men. In the
year 2008 alone, the American Cancer Society estimated 186,320
incidences and 28,660 mortalities of prostate cancer in the United
States (Cancer Facts and Figures, 2008). The disparity between can-
cer incidence and the associated mortality rates implies that,
although prostate cancer is the most common cancer in US men,
only a small proportion of prostate cancer cases will be life-threat-
ening (Hautmann et al., 2000). Those life-threatening prostate can-
cers are often known as ‘‘clinically-significant” prostate cancers,
which are loosely defined as cancers that are rapidly growing,
aggressively infiltrating the surrounding normal tissue and/or
highly likely to spread to other parts of the body (Albertsen,
1996; Singh et al., 2004; Siu et al., 2005). Indeed, clinical signifi-
cance of prostate cancer is the primary factor for clinical decision-
makings: those patients with clinically-significant prostate cancer
should be followed with immediate treatment; whereas those with
clinically-insignificant prostate cancer should be only followed
with watchful waiting. Therefore, accurate evaluation of cancer sig-
nificance becomes crucial for effective cancer management.
Evaluation of cancer significance is a challenging task, since it
requires accurate identification of prostate cancer and accurate
assessment of cancer spatial extent. Generally, cancer significance
can be evaluated either directly or indirectly; while the direct way
is ideal, it is the indirect way that is more practical and that we will
follow in this paper. Actually, the direct way is to carefully examine
the cancer prognosis in a series of longitudinal follow-ups. How-
ever, this is often impractical, mostly due to its long study time
and high clinical cost, and due to the lack of a diagnostic tool that
can accurately identify cancer in vivo. In the absence of longitudi-
nal follow-ups, clinical practice often follows the indirect way – to
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estimate certain surrogate markers at one time instance, and use
the estimated surrogate markers to indirectly evaluate cancer sig-
nificance. The commonly-used surrogate markers include cancer
volume, stage, grade, age, genetic factors and ethnic factors. Of
those, two surrogate markers are perhaps most important: cancer
volume and Gleason Score (a cancer grade descriptor scored 2–10,
higher score indicating more aggressive cancer and worse progno-
sis (Gleason, 1977)). This paper follows this indirect way of evalu-
ating cancer significance and aims to improve the estimation
accuracy for cancer volume (CV) and Gleason Score (GS), the two
most important surrogate markers.
1.2. Existing methods
Currently, estimation of CV and GS relies on either imaging
techniques (e.g., Futterer et al., 2005; Akin and Hricak, 2007; Des-
ouza et al., 2007; Hricak et al., 2007) or biopsy procedures (e.g.,
Hodge et al., 1989; Siu et al., 2005; Kibel, 2007; Chen et al.,
1997; Sofer et al., 2003; Shen et al., 2004; Zhan et al., 2007).
Although imaging techniques, especially the fast-evolving mag-
netic resonance imaging (MRI), have the advantage in their non-
invasive nature, they suffer greatly from the modest sensitivity
and specificity, a drawback that is commonly recognized in the
prostate imaging literature (e.g., Hricak et al., 2007; Kirkham
et al., 2006). In the absence of an imaging modality that could accu-
rately and reliably diagnose prostate cancer at the current stage,
prostate biopsy continues to be the standard procedure for esti-
mating CV/GS. Generally, biopsy estimates CV/GS by sampling
the prostate at a number of locations via biopsy needles. The
biopsy-sampled prostate tissue then undergoes microscopic exam-
inations, revealing cancer presence/absence and cancer pathology.
However, as addressed below, using existing biopsy procedures to
estimate CV/GS is often limited in two respects.
First, the sampling locations in the current biopsy procedures
are often suboptimal. In most biopsy procedures, the sampling
locations are determined in a random or empirical manner, leading
to mis-detection of cancer and mis-estimation of surrogate mark-
ers (Manseck et al., 2000; Fink et al., 2001). To cope with that, sev-
eral computer-assisted approaches (e.g., Sofer et al., 2003; Shen
et al., 2004; Zhan et al., 2007) have been developed. Their ap-
proaches maximized the probability of biopsy needles to intersect
with cancerous tissue, and hence remarkably improved the detec-
tion of cancer presence. However, they are not necessarily optimal
for the estimation of surrogate markers like CV and GS, since for
the estimation of CV/GS, the limited number of biopsy needles
has to not just intersect with cancerous tissue, but also represent
the spatial extent and pattern of cancer in the whole prostate. This
requirement renders the use of biopsy for CV/GS estimation fairly
challenging.
Second, the traditional criteria for surrogate marker estimation
are often suboptimal. For estimating CV, the traditional criterion is
the percentage of positive biopsies (e.g., Sebo et al., 2000) – more
positive biopsies needles indicate larger cancers. This criterion,
although quite intuitive, may fail in certain circumstances. As illus-
trated in Fig. 1, it will incorrectly yield the same percentage of po-
sitive biopsies (2 out of 6 in this case) for two prostates whose CV
values are substantially different. A possible solution to this prob-
lem would be increasing the number of sampling locations, as sug-
gested in Siu et al. (2005) and Stamatiou et al. (2007), but that
would substantially increase patient pain, and moreover it might
increase our risk of detecting clinically-insignificant prostate can-
cers, leading to unnecessary treatment and all pertinent side ef-
fects (Kibel, 2007). For estimating GS, on the other hand, the
traditional criterion is to analyze the limited number of prostate
tissue samples extracted by biopsy, find out two most common
glandular cancer patterns from those limited tissue samples, assign
to each of them a Gleason Grade (ranging from 1–5) and subse-
quently add the two Gleason Grades together (Gleason, 1977).
However, several studies (e.g., Cookson et al., 1997; Narain et al.,
2001) pointed out that the biopsy estimated Gleason Score (usually
known as ‘‘clinical Gleason Score”, or cGS) is often different from
the actual Gleason Score obtained after the prostate removal (usu-
ally known as ‘‘pathological Gleason Score”, or pGS). In other
words, using biopsy-extracted cGS to estimate the actual pGS is
subject to mis-estimations. And worse, such mis-estimation might
be substantial in a considerable proportion of cases (Johnstone
et al., 2007). To minimize mis-estimations for both CV and GS, an
ideal estimation criterion should comprehensively consider the
biopsy outcomes from all biopsy locations, in a sophisticated, per-
haps highly non-linear way that could effectively reflect the spatial
pattern of cancer. Actually, this novel, cancer-spatial-pattern-based
estimation criterion is one of the major contributions in our study,
as will be addressed later in this section.
1.3. The proposed method
This paper presents optimized biopsy procedures specifically
designed for estimating cancer volume (CV) and Gleason Score
(GS), two of the most important surrogate markers for the clinical
significance of prostate cancer. In our study, the estimation for
CV/GS is binary (high vs. low) instead of continuously-valued, so
as to better relate to the clinical decisions that tend to be binary:
immediate treatment for CV/GS values above certain clinical
threshold, or ‘‘watchful waiting” otherwise.
Our approach assumes that, prostate cancers having different
(high vs. low) CV/GS values may exhibit different spatial patterns,
which could be properly sampled by optimally-placed biopsy nee-
dles. By ‘‘spatial pattern”, we mean spatial distribution of cancer
reflected by the biopsy outcomes at all sampling locations. For in-
stance, if we order the biopsy locations in Fig. 1 from base to apex,
right to left, and denote the biopsy outcome at each biopsy location
to be 1 for cancer positive and 0 otherwise, we will observe spatial
cancer pattern of [1 0 0 0 0 1] for the first patient and [0 1 1 0 0 0]
for the second patient. In this way, CV values of those two patients
could be effectively estimated/differentiated, because the pattern
of two positive biopsies next to each other (in the second patient)
most probably implies cancer distributed in a larger, connected
area than the pattern of two positive biopsies far apart (in the first
patient). Actually, as will be demonstrated both qualitatively in
Section 2.3 and quantitatively in Section 3.2, the spatial pattern
of cancer is a robust estimation criterion with consistent high esti-
mation accuracy in the population under study.
Based on the assumption of using spatial cancer pattern for esti-
mation, our approach combines image analysis and pattern classi-
fication tools in a statistical atlas-based population study. To learn
the differences of spatial cancer patterns between the subpopula-
Fig. 1. A typical scenario where mis-estimation occurs when using the commonly-
adopted estimation criterion for CV. Black solid dots represent the biopsy locations
in clinical routines. The red regions represent prostate cancer regions. Please refer
to text for more details. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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tions having different (high vs. low) CV/GS values, our approach
first constructs statistical cancer atlases from histological images
of a cohort of surgically-extracted prostate specimens. Then, the
optimal biopsy locations are determined in a feature selection for-
mulation, so that biopsy outcomes (either cancer presence or ab-
sence) at those locations could altogether differentiate between
the subpopulations of high and low CV/GS specimens at the best
rate. The optimized biopsy locations are thereafter used to esti-
mate whether a new-coming prostate cancer patient has high or
low CV/GS values, in a SVM-based binary classification formula-
tion. The estimation accuracy and the generalization ability of
our approach are evaluated by the classification rates and the asso-
ciated receiver-operating-characteristic (ROC) curves in cross
validations.
Compared with optimized biopsy procedures previously devel-
oped in Sofer et al. (2003), Shen et al. (2004) and Zhan et al. (2007),
our approach has the following three merits. The first and foremost
merit lies in the objective: previous ones aim to improve the detec-
tion of cancer presence; ours aims to estimate surrogate markers
for the clinical significance of prostate cancer, which is a far more
important yet far more difficult problem. Detecting cancer pres-
ence, the objective in their studies, requires that at lease one
biopsy needle intersects with cancer; whereas estimating surro-
gate markers, the objective in our study, has an additional require-
ment – it requires biopsy needles to sample the prostate in a way
that can reflect the spatial cancer patterns. The second merit is the
high generalization ability in our approach. The high generalization
ability stems from the sparsity of SVM in the feature selection and
pattern classification formulations; it also arises from using the no-
vel, more reliable spatial-pattern-based estimation criterion in the
classification formulation. The third merit of our approach is its
robustness to the almost inevitable uncertainties of needle place-
ment in clinical practice. The robustness is obtained by selecting
optimized biopsy locations that have high estimative powers not
only at themselves but also in their neighborhoods. Moreover, un-
like many optimization processes, whose performances are heavily
dependent on the optimization parameters being used, our biopsy
optimization process is relatively stable in terms of estimation
accuracy, regardless of the variations in the optimization parame-
ters and the training populations, as will be shown in the sensitiv-
ity analysis in Section 4.
The remainder of this paper is organized as follows: Section 2
details our framework. Section 3 shows the results for the opti-
mized biopsy procedures and their estimation/classification accu-
racies. Section 4 examines the robustness of our framework with
regard to the variations in the optimization parameters and training
populations. Finally, Section 5 discusses and concludes this paper.
2. Method
2.1. General framework
As sketched in Fig. 2, our approach consists of three compo-
nents: atlas construction (via image registration), biopsy location
optimization (via feature selection) and surrogate marker estima-
tion based on the optimized biopsy locations (via binary classifica-
tion). Those three components are elaborated in the subsequent
Sections 2.3–2.5. Prior to that, we will first describe data acquisi-
tion in Section 2.2.
2.2. Data acquisition
We have collected a population of 83 prostate specimens
fpnjn ¼ 1;2; . . . ;Ng ðN ¼ 83Þ that have undergone radical prosta-
tectomy (a surgery for prostate removal). These specimens are
available from the tissue bank of the Center for Prostate Disease
Research (CPDR) (http://www.cpdr.org). They are aged 60:4 6:3
years old (min 44, max 73), with pre-biopsy prostate-specific anti-
gen (PSA) values at 12:59 18:52 ng/mL (min 0.7, max 138), and
the actual prostate sizes at 92:7 41:1 g (min 46, max 165, 1 g in
weight is approximately equal to 1 cc in volume).
Those specimens are further divided into different subpopula-
tions, according to surrogate marker values that are known from
pathological analysis. When different surrogate marker is used,
the subpopulation division might be different. Specifically, when
CV/GS is the surrogate marker under estimation, those specimens
are divided into a subpopulation of 46/47 specimens with high
CV/GS and the remaining 37/36 with low CV/GS. Here, the thresh-
olds of 0.5 cc for CV and 6 for GS are adopted from clinical conven-
tions. After the division, each specimen pn is assigned with a class
label CðpnÞ,
CðpnÞ ¼
þ1 if pn has high surrogate marker value
1 otherwise

ð1Þ
As shown in Table 1, the subpopulation divisions have uncov-
ered three interesting facts that are worth noting. First, almost
one quarter of the specimens have low CV and low GS, an indica-
tion that their cancers might be clinically-insignificant. This is a
fundamental issue in clinical practice: some patients may be de-
tected with cancer by repeated biopsies; however, their cancers
might be insignificant so that they should not be followed with
prostatectomy. This fact underlines the importance of estimating
their surrogate markers and clinical significance as what we are
discussing in this paper. Second, being high in one surrogate mar-
ker does not necessarily indicate being high in the other (19.3%
Fig. 2. Systematic sketch for the general framework of our approach.
Y. Ou et al. / Medical Image Analysis 13 (2009) 609–620 611
has high GS but low CV, while 18.1% has low GS but high CV).
Therefore, the class labels for a same specimen might be different
when different surrogate markers are under estimation. For the
same reason, different atlases and different optimized biopsy pro-
cedures are needed for estimating different surrogate markers.
Third, overall, the prostate specimens having high and low surro-
gate markers in our study are almost half and half (or, more accu-
rately, 56% and 44%), so the dataset is not noticeably biased when it
is used to reflect different cancer patterns in subpopulations hav-
ing different CV/GS values.
To also present pathologists-defined cancer ground truth, histo-
logical images have been collected for all specimens. During the
histology collection, each specimen was whole-mounted, step-sec-
tioned at 2.25 mm intervals and H/E stained at 5 lm thickness,
leading to series of 2D histological slices with pathologically-de-
fined cancer ground truth (e.g., red regions in Fig. 3); then, the
series of 2D histological slices were reconstructed into a 3D histo-
logical image, which will be used to reveal 3D cancer distributions
in the subsequent atlas constructions.
2.3. Constructing statistical atlases
From those acquired population data, our study first constructs
statistical atlases to observe different cancer spatial patterns from
subpopulations having different surrogate marker values. This will
provide qualitative support for using the spatial pattern of cancer
as a reliable estimation criterion. Generally, a statistical atlas is a
model of the object/organ of interest, usually represented as the
probability of certain anatomic structure or certain types of tissue
(in our paper, cancerous tissue) being present at each voxel in the
3D coordinate system (Shen et al., 2004; Frangi et al., 2002; Park
et al., 2003; De Craene et al., 2004).
Basis to the atlas construction is to spatially normalize the 3D
histological images across specimens into a common prostate
space S, which has regular shape and has 256 256 124 image
voxels. The spatial normalization is done by a 3D surface-based
non-rigid image registration method (Shen et al., 2001). Fig. 3
shows the common prostate space and a typical histological image
before and after the spatial normalization, in both 3D and 2D
views. The spatial normalization preserves the zonal anatomy of
the prostate, as demonstrated in Zhan et al. (2007), so that after
normalization, the same spatial coordinates will correspond to
approximately the same anatomic locations across specimens.
Then, the statistical cancer atlases are constructed by merging
the spatially-normalized histological images for each subpopula-
tion. Results are shown in Fig. 4. In the atlases, the brightness of
each voxel represents the probability of cancer occurrence in the
subpopulation of interest. From visual inspections, it is not difficult
to observe that, statistically, subpopulations having different sur-
rogate marker values do exhibit different spatial patterns (distribu-
tions) of caner. Moreover, some candidate biopsy locations (e.g.,
blue dots in Fig. 4) can be intuitively observed, since biopsy out-
comes (either cancer positive or negative) at those locations would
most probably differentiate between different subpopulations.
How to automatically and accurately select the optimal biopsy
locations is described in the following sub-sections.
2.4. Determining optimal biopsy locations by feature selection
In this section, the problem of selecting optimal biopsy loca-
tions is converted to a feature selection formulation. Basis to this
conversion is the feature extraction step, which connects each po-
tential biopsy location in the common prostate space with a fea-
ture in the feature space.
Table 1
Number of specimens in the subpopulations having high or low CV/GS. The thresholds
(0.5 cc for CV and 6 for GS) are adopted from clinical conventions.
High CV (P0.5 cc) Low CV (<0.5 cc) Total
High GS (P6) 31 (37.3%) 16 (19.3%) 47 (56.6%)
Low GS (<6) 15 (18.1%) 21 (25.3%) 36 (43.4%)
Total 46 (55.4%) 37 (44.6%) 83 (100%)
Fig. 3. The common prostate space (a) and the histological image of a typical specimen before (b) and after (c) the 3D spatial normalization, in both 3D (top row) and 2D
(bottom row) views. Red regions are cancer ground truths labeled by pathologists. The bottom row shows the central slice in the coronal orientation. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
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2.4.1. Feature extraction: connecting each potential biopsy location to
a feature
A potential biopsy location u 2 S  R3 is connected to a feature
BðuÞ, provided that BðuÞ is the ‘‘biopsy outcome” of the biopsy nee-
dle centered at location u. This connection is further explained
below.
Mathematically, a biopsy needle can be modeled as a semi-cyl-
inder QðOÞ,
QðOÞ ¼ ðx; y; zÞj
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðx OxÞ2 þ ðy OyÞ2
q
6 r;

0 6 y Oy 6 r; kz Ozk 6 l

ð2Þ
where O ¼ ðOx;Oy;OzÞ 2 R3 is the center, r is the base radius and l is
the semi-length of the semi-cylinder (c.f. Fig. 5). Since r = 1.5 mm
and l = 6 mm are usually determined from clinical conventions,
the semi-cylinder shaped biopsy model has only one parameter –
the center O.
When this semi-cylinder shaped biopsy needle is centered at a
potential biopsy location u 2 S  R3, it will extract a piece of pros-
tate tissue also centered at u. From an image analysis point of re-
view, the extracted piece of prostate tissue can be modeled as
TissueðuÞ ¼ QðuÞ \ S ð3Þ
This piece of prostate tissue will exhibit either cancer presence or
cancer absence, denoted as ‘‘biopsy outcome” BðuÞ,
BðuÞ ¼
1 if cancer present in TissueðuÞ
0 otherwise

ð4Þ
In this way, each specimen pn can be represented by a high-dimen-
sional feature vector Fðpn; fu1;u2; . . . ;uMgÞ, i.e.,
Fðpn; u1;u2; . . . ;uMf gÞ ¼ Bpn ðu1Þ;Bpnðu2Þ; . . . ;BpnðuMÞ
 
ð5Þ
where u1;u2; . . . ;uM are all possible biopsy locations, with M being
the total number of them. The connection between each potential
biopsy location and a feature is also illustrated in Fig. 6.
2.4.2. Feature selection: finding optimized biopsy locations
After connecting each potential biopsy location u with a feature
BðuÞ in the feature extraction step, it naturally follows that the
problem of selecting K optimal biopsy locations fus1 ;us2 ; . . . ;usK g
in the common prostate space S can be translated to the selection
of a subset of K best features fBðus1 Þ;Bðus2 Þ; . . . ;BðusK Þg in the fea-
ture space, i.e.,
f pn; fs1; s2; . . . ; sKgð Þ ¼ Bpn ðus1 Þ;Bpn ðus2 Þ; . . . ;Bpn ðusK Þ
 
ð6Þ
such that under certain classifier whose decision function is Z½, the
classification result Z f ðpn; fs1; s2; . . . ; sKg½  could agree with pre-
known class label CðpnÞ at the best rate, for all specimens
n ¼ 1;2; . . . ;N, i.e.,
s1; s2; . . . ; sKf g ¼ arg min
ft1 ;t2 ;...;tK gf1;2;...;MgXN
n¼1
Z f pn; ft1; t2; . . . ; tKgð Þ½   CðpnÞk kL1 ð7Þ
Fig. 4. Statistical atlases constructed from subpopulations having different (high vs. low) surrogate marker values. Blue dots represent intuitively-observed biopsy locations
where different subpopulations can be differentiated. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
Fig. 5. Modeling a biopsy needle as a semi-cylinder. (a) A typical biopsy needle –
when it is placed into the prostate, the ‘‘cut-out” part will extract a piece of prostate
tissue; (b) the cut-out part of the biopsy is modeled as a semi-cylinder, with center
O, base radius r and semi-length l. The values of r ¼ 1:5 mm and l ¼ 6 mm are
determined by clinical conventions.
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Here f ðpn; ft1; t2; . . . ; tKgÞ denotes the biopsy-extracted multivariate
information (spatial-pattern-vector) at those K locations ft1; t2; . . . ;
tKg from training prostate specimen pn.
2.4.3. Solving the feature selection problem
Selecting K out of M features is a challenging task when we have
K  M in our problem. Indeed, K , the number of optimal biopsy
locations, is typically ranged from 6 to 12 (keep in mind that, in or-
der to reduce patient pain and the biopsy-induced morbidities, a
small K value is usually preferred). Meanwhile, when the image
space is discretized, M, the total number of all possible biopsy loca-
tions, is usually in the millions.
Feature selection methods have been extensively investigated
in the machine learning community. Their common purpose is of-
ten to determine a small number of optimal features for increasing
both the accuracy and the generalization ability of classification.
During the past two decades, a variety of methods have been
developed for feature selection, such as Adaboost (Freund and
Schapire, 1999) and decision trees (Quinlan, 1986). In Guyon and
Elisseeff (2003), Guyon and Elisseeff summarized that the most fre-
quently used feature selectors can be broken down into two types:
feature ranking and subset selection. They both have merits and
drawbacks. Particularly, feature ranking methods rank features
according to their individual predictive powers and simply pick
up a number of top-ranked features – this type of methods are
computationally economic, but will often lead to highly sub-opti-
mal solutions, as they do not evaluate the statistical correlations
among features. Subset selection methods, on the other hand, se-
lect a subset of features that altogether have the highest predictive
power – this type of methods will lead to globally optimal solu-
tions, but are often time-consuming or even computationally pro-
hibitive when the total number of features is large, as in our case.
In practice, these two types of feature selectors are often jointly
used: to initialize with feature ranking and to refine with subset
selection. We adopt this two-step strategy in our approach.
Step 1: Feature Ranking. Features are first ranked by their individ-
ual estimative powers. The estimative power of the ith fea-
ture (hence the potential biopsy location ui) is measured
by the Pearson’s correlation coefficient with class labels
CðpnÞ across all specimens pnðn ¼ 1;2; . . . ;NÞ, i.e.,
qðuiÞ¼
PN
n¼1 BpnðuiÞBðuiÞ
 
CðpnÞC
	 

ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPN
n¼1 BpnðuiÞBðuiÞ
 2h i PN
n¼1 CðpnÞC
	 
2 s ð8Þ
Here BðuiÞ ¼ 1N
PN
n¼1Bpn ðuiÞ is the mean biopsy outcome at
location ui across all specimens and C ¼ 1N
PN
n¼1CðpnÞ is the
mean class label across all specimens. A higher correlation
coefficient qðÞ represents stronger estimative/discrimina-
tive power, since agreement of the biopsy outcome at a given
location with the known class label of more specimens im-
plies that this given location has higher estimative value
for class labels. Out of the total of M features, this step will se-
lect m top-ranked features (K < m M). The value of m is
experimentally found having little influence to the final esti-
mation/classification rate as long as m > 4K is satisfied. Note
that, to account for the almost inevitable needle placement
errors within an expected range in clinical practice, features
(hence biopsy locations) should be selected if they have high
estimative powers not only at themselves, but also at their
neighborhoods. Therefore, a high ranking (or a high estima-
tive power) does not necessarily guarantee a feature (or a
biopsy location) to be selected; rather, we would prefer the
ith biopsy location by seeking
i ¼ arg max
j2f1;2;...;Mg
qðujÞ þ
1
jHðujÞj
X
ul2HðujÞ
qðulÞ
2
4
3
5 ð9Þ
where HðujÞ denotes the neighborhood of a potential
biopsy location uj and j  j is the cardinality of a set. The first
term in Eq. (9) represents high estimative power in the can-
didate feature (biopsy location) itself, and the second term
represents necessarily high estimative power in the
neighborhood.
Step 2: Subset selection. Within the reduced number of features,
subset selection method can be used to select a subset of
features that altogether has the highest estimative power.
We have used a support vector machine (SVM)-based sub-
set selector, which selects subset of features through iter-
ative backward sequential elimination (BSE) and forward
sequential inclusion (FSI) of features (Fan et al., 2007). In
each iteration, the BSE (or FSI) procedure removes (or
adds) one feature that minimizes the Gaussian-kernel
SVM-based leave-one-out error bound (Rakotomamonjy,
2003), compared with removing (or adding) other fea-
tures. The leave-one-out error bound is known as an unbi-
ased estimator for the generalization ability of a classifier
trained on all but one available samples, which is
4R2kwk2 for SVM, where R is the radius of the smallest
hyper-ball containing all mapped feature vectors by some
Fig. 6. Feature extraction step connects each potential needle location uj with a feature BðujÞ. This connection is the basis to the conversion of the problem of selecting
optimal biopsy locations into the feature selection formulation.
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kernel function Uð; Þ, and w is the normal vector to the
separation hyper-plane in the SVM formulation. The algo-
rithm stops when there is no better feature to be removed
or added into the subset. The output is the set of K optimal
features, and hence the K optimal biopsy locations
fus1 ;us2 ; . . . ;usK g, which, as a whole, have the highest esti-
mative/discriminative power.
2.5. Estimating surrogate markers by classification
The optimal biopsy locations determined in the population of
prostate specimens are then used to estimate whether a new-com-
ing prostate cancer patient has high or low surrogate marker val-
ues. Note that, in this paper, the surrogate marker estimation
problem is formulated as a binary classification problem rather
than a more intuitive continuous-valued regression problem, be-
cause the binary estimation results better relate to the clinical
decisions that tend to be binary: immediate treatment for CV/GS
above some clinical thresholds, or ‘‘watchful waiting” otherwise.
Actually, the real application of the optimized biopsy proce-
dures requires warping/mapping the optimized locations from his-
tological image space of the population into the intra-operative
transrectal ultrasound (TRUS) or MR image space of the specific pa-
tient under biopsy. Such a registration should be deformable and
multi-modal (histology-TRUS/MRI). Furthermore, since histological
images used in this paper contain prostate only, whereas the intra-
operative TRUS or MR images usually contain prostate as well as all
the surrounding tissue/organs, it would be plausible to segment
the prostate from the intra-operative TRUS/MR images prior to
the registration. The segmentation can be obtained by a 3D
deformable model that was previously developed in our group
(Zhan and Shen, 2006). After segmentation, we can register the
prostate surfaces between histological and TRUS/MR images using
the same deformable surface matching method (Shen et al., 2001)
as we used to register multiple histological images in the atlas
reconstruction part; or, we can register prostate from histological
and TRUS/MR images by more accurate voxel-wise attribute
matching methods that are recently developed in our group (Ou
and Davatzikos, 2009; Ou et al., 2009; Zhan et al., 2007). Since
the prostate segmentation and histology-TRUS/MRI registration
algorithms are beyond the scope of this paper, we thereafter sim-
plify the real biopsy application problem by assuming that the
optimized biopsy locations have already been warped to the spe-
cific patient under biopsy, and those optimized biopsy locations
are still denoted as fus1 ;us2 ; . . . ;usK g.
When a new-coming patient is under examination, a number of K
needles will be placed at the optimized biopsy locations
fus1 ;us2 ; . . . ;usK g. Biopsy outcomes from those locations can be
stacked into a multivariate vector Bðus1 Þ;Bðus2 Þ; . . . ;BðusK Þ
 
, repre-
senting spatial pattern of cancer. Based on the biopsy-extracted can-
cer spatial patterns, this patient could be estimated/classified to
have high or low surrogate markers by an appropriate pattern
classifier.
Theoretically any pattern classifier can be used for estimation/
classification, such as artificial neuron network, naive Bayesian clas-
sifier, multivariate discriminant (Zhao et al., 1998) and support vec-
tor machine (SVM) (Burges, 1998). We have used the non-linear SVM
classifier based on the Gaussian kernel function
Uðxi; xjÞ ¼ exp
kxixjk2
2r2
	 

. Generally, SVM is a supervised classifier
that divides the two classes of training samples by a separation hy-
per-plane that maximizes the margin distance between the two clas-
ses (Burges, 1998). When the linear SVM is used, the separating
hyper-plane resides in the original feature space; whereas on the
other hand, when non-linear SVM is used, the separating hyper-
plane resides in the mapped feature space (Hilbert space).
We chose SVM because of three reasons. First, SVM has been
empirically demonstrated as one of the most powerful and compu-
tationally efficient pattern classifier, with successful applications
in numerous clinical problems like ours (Brown et al., 2000; Cai
et al., 2007; Furey et al., 2000; Guyon et al., 2002; Osuna et al.,
1997; Ou et al., 2007; Verma et al., 2008). Second, since our feature
selection is SVM-based, a coupled classification that is also SVM-
based could probably achieve the highest accuracy. Third, SVM
classifier can improve the generalization ability of our approach,
because of its implicit sample selection mechanism and the spar-
sity characteristics. This is especially suitable for our study when
the number of features (M) is far greater than the number of train-
ing samples (N).
3. Results
3.1. Optimized biopsy procedures
The results for the optimized biopsy procedures are shown in
Fig. 7. Following clinical conventions, biopsy needles are placed
into the prostate in either transrectal (posterior to anterior inser-
tion) or transperineal (apex to base insertion) settings. Different
procedures are optimized for estimating different surrogate mark-
ers, for the reason that being high in one surrogate marker does not
necessarily imply high in the other, as can be observed in Table 1.
In contrast to existing biopsy procedures (e.g., Chen et al., 1997;
Epstein et al., 1997; Fink et al., 2001; Hodge et al., 1989; Sofer
et al., 2003; Shen et al., 2004; Zhan et al., 2007), the biopsy needles
in our optimized procedures are ordered according to their impor-
tance/priority, so as to better delineate the spatial patterns of can-
cer. In the upper-left subfigure of Fig. 7, the actual physical
distance between the center of the first and the fourth needles is
18.44 mm, and the distance between the third and the fourth nee-
dles is 15.42 mm, almost ten times of the radius of the needle.
To gain more understanding of how the optimized procedures
are used to estimate, for instance, CV, we can visually superimpose
the optimized transrectal procedure in the upper-left part of Fig. 7
onto the statistical atlases of high and low CV specimens in the top
row of Fig. 4. Then we can observe that, specimens having high CV
values tend to have positive biopsies at the first, second and fourth
biopsy locations, while specimens having low CV values do not.
Similar observations could be drawn for estimating GS values.
All experiments were operated in C code on a 2.8 G Intel Xeon pro-
cessor with UNIX operation system. In constructing the statistical at-
lases, it took 26 h to normalize all 83 specimens onto the common
prostate space (about 25 min each), which could be reduced to
approximately 3 h by paralleling the processes on 8 CPUs. Another
1.5 h is needed for the optimization of biopsy locations and the sub-
sequent binary classification. It is worth noting that the relatively
large computational cost is not a serious problem for clinical applica-
tions, since both the statistical atlas construction and biopsy optimi-
zation are computed offline rather than real-time.
3.2. Estimation accuracy of the optimized biopsy procedures
To evaluate estimation accuracy, our optimized biopsy proce-
dures are applied to the collected prostate specimens (the ones de-
scribed in Section 2.2) with known surrogate marker values. Both
leave-one-out and 10-fold cross validations are carried out. That
is, we train the optimized biopsy procedures by all but one (or
one-tenth) prostate specimens and test on the left-out one (or
one-tenth) specimen, repeating until every specimen (or every
set of one-tenth of specimens) has been left out once.
In cross validations, the estimation accuracy is measured
by classification rates and the associated receiver-operating-
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characteristic (ROC) curves. (Recall that the estimation problem is
formulated as a binary classification problem to accommodate to
the clinical decisions that tend to binary). Mathematically, classifi-
cation rate is the fraction of the prostate specimens that have been
correctly classified/estimated in terms of high vs. low in surrogate
marker values, i.e.,
EstimationAccuracy ¼ ClassificationRate
¼ 1
N
XN
n¼1
1 ZSVM f pn; fs1; s2; . . . ; sKgð Þ½  ¼ CðpnÞð Þ
ð10Þ
where 1ðXÞ is the logic function that equals 1 when the event X is
true and 0 otherwise, ZSVM ½f  is the SVM decision function which
outputs a class label (‘‘þ1” for high and ‘‘1” for low surrogate mar-
ker value), based on the input feature vector f . In the ROC curve, the
relationship between the true positive rate (TPR) and false positive
rate (FPR) are plotted. TPR (also known as ‘‘sensitivity”) and FPR
(also known as ‘‘1-specificity”) are defined as
TPR ¼
PN
n¼11
CðpnÞ ¼ þ1ð Þ&&
ZSVM f pn; fs1; s2; . . . ; sKgð Þ½  ¼ þ1ð Þ
 
PN
n¼11 CðpnÞ ¼ þ1ð Þ
FPR ¼
PN
n¼11
CðpnÞ ¼ 1ð Þ&&
ZSVM f pn; fs1; s2; . . . ; sKgð Þ½  ¼ þ1ð Þ
 
PN
n¼11 CðpnÞ ¼ 1ð Þ
ð11Þ
Fig. 8 shows the estimation/classification accuracy and ROC
curves for the leave-one-out cross validations. The estimation/clas-
sification rates of 94.79% (or 81.93%) and the areas under ROC curve
(AUC) of 0.98 (or 0.83) have been observed, when estimating CV (or
GS) by seven optimized needles in the transperineal setting. Simi-
larly, when 10-fold cross-validation mechanism is used, the classi-
fication rates for these two cases are 92.59% and 88.75%,
demonstrating a good generalization ability of our approach. More
details of the estimation accuracy can be found in Table 2 for differ-
ent biopsy settings in estimating different surrogate markers.
In Fig. 8(A1&A2), the estimation/classification accuracies are
also recorded when different numbers of biopsy needles are opti-
mized. An interesting finding is that, as long as more than 6 or 7
biopsy needles are optimized, there is no added value for addi-
tional number of biopsy needles. This finding underlines the
importance of optimizing biopsy locations other than increasing
the number of biopsy locations.
4. Sensitivity analysis
Our framework is essentially an optimization problem in a pop-
ulation study – it optimizes biopsy locations, and the optimum is
defined on the collected population of prostate specimens. Indeed,
in most optimization systems or population studies like ours, a
common problem is that, the performance of the system or study
is usually sensitive to the variations in the optimization parame-
ters or the input (training) populations. Those sensitive, or unsta-
ble, estimators would obviously have limited clinical use.
Therefore, the question herein is, whether our framework is sensi-
tive/unstable in these respects, and if it is, to which extent.
This section aims to evaluate the sensitivity of our framework
with regard to two types of variations that can potentially limit
the generalization ability of our framework: (1) variations in the
optimization parameters and (2) variations in the training popula-
tions. They are described in Sections 4.1 and 4.2, respectively.
4.1. Effects of variations in the optimization parameters
The effects of two major optimization parameters are examined
in this section. The first major parameter is the threshold T for the
Fig. 7. Optimized biopsy locations for estimating cancer volume (top row) and Gleason Score (bottom row), by using seven needles in both transrectal and transperineal
settings.
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Pearson’s correlation coefficient. This threshold T is introduced to
encourage statistical independence between any two features
selected, and therefore to avoid several needles being selected
around a single location. That is, in the feature ranking part
(‘‘Step 1” in Section 2.4.3), we eliminate those features that have
high correlation (>correlation threshold T) with the already
selected top-ranked features, before we proceed to select the next
top-ranked feature. The second major parameter is the Gaussian
kernel size r for the non-linear SVM. It is introduced in SVM-based
feature selection and SVM-based binary classification. Ideally, the
estimation/classification accuracy of our optimized biopsy proce-
dures should be consistent/stable, regardless of the variations in
the threshold T and the SVM kernel size r.
In our experiments, one parameter is fixed while the other var-
ies, and the robustness of our approach is demonstrated by the
consistency in the resultant estimation/classification rates and
ROC curves, as shown in Fig. 9.
4.2. Effects of variations in the training population
In any population-based study like ours, it is understandable
that different populations of subjects might yield different optimi-
zation results. The key question is to which extent.
To answer this question, we have simulated new populations
of prostate specimens by a statistical simulation method known
as bootstrap (Efron and Tibshirani, 1986; Manly, 2006). In statis-
tical inference, bootstrap evaluates an estimator (e.g., estimation/
classification rates in our case) of the original population by sim-
ulating new populations via resampling the original population
with replacement (Hesterberg et al., 2005). ‘‘Resampling with
replacement” means that, after choosing a prostate specimen in
the original population, we put it back before choosing the next
specimen, until we have picked up the same number of prostate
specimens as that in the original population. As a result, some
prostate specimens will be selected multiple times while others
not even once. For instance, if we are considering an estimator
(e.g., the mean value) from an original population of natural
numbers {10, 45, 20, 50, 38} and we want to establish a stan-
dard deviation for the original estimator value, we could resam-
ple the original population with replacement and thereby obtain
an infinite number of simulated populations, such as {10, 20, 10,
38, 50}, {45, 20, 38, 45, 20}, and so forth. Each simulated popu-
lation will yield one ‘‘simulated estimator value” and a large
number (usually greater than 10 times the sample size in the
original population) of such simulated estimator values will help
us establish the standard deviation for the original estimator
value.
Using the bootstrap method, we have simulated 850 popula-
tions, each having the same number (83) of specimens as the ori-
ginal population has and each leading to a cross-validated
classification rate, which altogether forms a bootstrapping distri-
bution of 850 classification rates, as shown in Fig. 10. This boot-
strapping distribution reveals the mean classification rate at
87.15% and the associated standard deviation at 5.79%. Small
standard variations are also found in transperineal/transrectal
Fig. 8. Estimation accuracy for CV (top row) and GS (bottom row), by the optimized biopsy procedures in transperineal settings. (A1&A2): Classification rate as a function of
the number of optimal needles. (B1&B2): ROC curve, where seven needles were used.
Table 2
Estimation accuracy in the leave-one-out cross validations, in terms of classification
rate and the area under the ROC curve (AUC). Here, seven biopsy needles are
optimized to estimate CV and GS, respectively.
Classification rate AUC
For CV (%) For GS (%) For CV For GS
Transrectal biopsy 93.75 78.54 0.96 0.79
Transperineal biopsy 94.79 81.93 0.98 0.83
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procedures for estimating CV/GS, prompting the robustness of our
framework with regard to the variations in the training population.
We chose bootstrap over Monte Carlo, another widespread sim-
ulation method because Monte Carlo simulation generates new
samples from a prior knowledge of the underlying sample distribu-
tion, while bootstrap method simply re-samples the original sam-
ples without any prior knowledge of the underlying sample
distribution. Bootstrap simulation method is therefore more suited
in our study, since we do not have a good probabilistic cancer
growth model for generating new prostate cancer specimens.
5. Discussion
In this paper, we developed optimized biopsy procedures spe-
cifically designed to estimate cancer volume (CV) and Gleason
Score (GS), which are two of the most important surrogate markers
for clinical significance of prostate cancer. To the best of our
knowledge, our study is the first to present optimized biopsy pro-
cedures, as well as the novel estimation criterion, that can be used
to specifically estimate surrogate markers for cancer significance.
We have assumed and demonstrated that, by optimally sampling
the spatial patterns of cancer, biopsy procedures could be used to
estimate/classify whether a prostate cancer patient has high or
low CV/GS values. In our framework, selecting the optimized
biopsy locations is formulated as a feature selection problem,
where we selected biopsy locations such that biopsy outcomes
from those locations could best differentiate between specimens
having different (high vs. low) surrogate marker values. Accord-
ingly, estimating surrogate markers is formulated as a binary clas-
sification problem, which estimates/classifies whether a new
patient has high or low surrogate marker values in a way that gen-
eralizes well. Moreover, our approach is designed with the ability
to account for the almost inevitable errors of needle placement
in clinical practice; it is also experimentally found to be robust
with regard to the major parameters in our optimization process
and with regard to the input training populations.
Fig. 10. Bootstrapping distribution of the classification rates in 850 simulated
populations. The mean and standard deviation is established at 87:18 5:79%, for
using transperineal optimized biopsies to estimate GS. Similar results are found in
transperineal/transrectal biopsy procedures when estimating CV/GS.
Fig. 9. Robustness of our approach in estimating GS, with regard to the variations of two major optimization parameters (threshold T and Gaussian kernel r). (A) T is fixed at
0.5, and r varies from 1 to 50 (transperineal setting) and (B) r is fixed at 20, and T varies from 0.4 to 0.8 (transrectal setting).
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In contrast to existing biopsy procedures, which mostly aim to
improve the detection of cancer presence, our study aims to esti-
mate surrogate markers for clinical significance of prostate can-
cer, which is a far more important yet far more difficult
problem. For detecting cancer presence in those existing proce-
dures, it is required that at least one biopsy needle can intersect
with cancerous tissue; whereas for estimating surrogater mark-
ers, the goal in our study, it is required that the multiple biopsy
needles must sample the prostate in a way that can reflect cancer
spatial pattern. Because of this fundamental distinction, this pa-
per has a completely different formulation from the existing ones.
As a result, our optimized biopsy procedures can provide substan-
tial information for the optimal treatment planning and effective
cancer management.
The surrogate marker estimation in this paper is binary (high
vs. low) instead of continuously-valued, because the binary esti-
mation better relates to the clinical decisions that tend to be bin-
ary: immediate treatment for surrogate marker values above
some clinical threshold, or ‘‘watchful waiting” otherwise. Mean-
while, we have developed different biopsy procedures for esti-
mating different surrogate markers (CV or GS). Reasons can be
found in Table 1: that being high in one surrogate marker does
not necessarily indicate high in the other. In occasions where
CV and GS do not agree with each other (in terms of high vs.
low), how to utilize the estimated CV and GS values to evaluate
clinical significance of prostate cancer becomes a quite challeng-
ing problem. Actually, other than CV and GS, there are numerous
other surrogate markers that will also contribute to the determi-
nation of the clinical significance of prostate cancer. Such
surrogate markers include, but are not limited to, age, genetic
factors and ethnic factors. Kibel stated in Kibel (2007): ‘‘The
40-year-old patient with a 0.5 cc tumor is of much greater
concern than the 80-year-old with a 1.0 cc tumor.” Till recently,
how to comprehensively use all those surrogate markers to con-
clude the cancer significance is still a challenging problem under
debate (Albertsen, 1996; Singh et al., 2004). Therefore, this paper
only discusses estimations of surrogate markers CV and GS, and
the further evaluation of cancer significance goes beyond the
scope of this paper.
Our study has yielded several interesting observations. Firstly,
we have observed in Fig. 8(A1&A2) that the increased number of
biopsy needles over 6 or 7 does not provide added estimative va-
lue, and should rather be avoided because of the marginal decrease
in estimation accuracy and the increase in patient pain as well as
the associated morbidities. This provides quantitative reference
for the ongoing debate about how many needles are appropriate
to balance between patient pain and the detection of clinically-sig-
nificant prostate cancers. Secondly, we have observed qualitatively
in Fig. 8 and quantitatively in Table 2 that, the estimation accuracy
for cancer volume is noticeably higher than that for Gleason Score.
A plausible explanation could be that cancer volume is a quantity
that is more closely correlated to the spatial pattern of prostate
cancer and could therefore be better sampled and estimated by
the optimally-placed biopsy needles. Generally, larger cancers are
expected to have grown closer to the capsule boundary than smal-
ler cancers; therefore needles placed in those locations would be
more likely to determine whether a tumor is large or small with
high accuracy. This prompts future investigations, especially from
the clinical perspective, of the correlations between cancer spatial
patterns and cancer surrogate markers.
The presented framework is general. It could thereby be readily
applied to different populations, different surrogate markers, dif-
ferent types of human cancer and even different clinical proce-
dures other than biopsy. For example, our framework could be
potentially used to find whether different patient groups (stratified
by ethnicity, age or PSA level) tend to develop clinically-significant
prostate cancers at different locations on statistical basis. Addition-
ally, it could also be used to guide focal radiotherapy or other spa-
tially-confined treatments to those locations that are statistically
more likely to develop clinically-significant prostate cancer, thus
increasing the treatment efficiency.
A potential limitation of our study is the relatively small sample
size: 83 prostate specimens might not be sufficient to accurately
represent cancer distributions in the entire population of prostate
cancer patients. Actually, this limitation is inherent to any ap-
proach attempting to derive cancer distribution (e.g., Sofer et al.,
2003; Shen et al., 2004; Zhan et al., 2007; Ou et al., 2008). A possi-
ble solution would be to encourage multi-institutional studies and
data sharing processes, so that larger sample size could be inde-
pendently acquired and the ‘‘true” cancer distribution could be
approximated with less bias. Meanwhile, we are planning to vali-
date our optimized biopsy procedures in new groups of patients,
initially via ex vivo biopsy of the surgically-extracted prostatecto-
my specimens.
In summary, we have presented an approach to derive opti-
mized biopsy procedures, for estimating cancer volume and
Gleason Score, two of the most important surrogate markers for
clinical significance of prostate cancer. More validations and in-
ter-institutional collaborations are expected in the future.
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